RIBER Secures ROSIE Order from US Quantum Computing Firm

RIBER announced on 8 September  2025 that it has secured its first United States order for a ROSIE system from a leading quantum‑computing company. The order marks a pivotal moment for the company, signalling that the fully automated ROSIE platform—designed for the precise growth of thin oxide layers on 300‑mm silicon wafers—has earned the confidence of a high‑profile U.S. customer in the quantum‑technology sector. The deal follows RIBER’s earlier collaboration with the Novo Nordisk Foundation Quantum Computing Programme (NQCP) in Denmark, underscoring the platform’s growing credibility across the global quantum‑computing ecosystem.

The ROSIE system is engineered to deposit barium titanate thin films with exceptional uniformity and defect control, a material that is increasingly recognised as a cornerstone for integrated electro‑optic modulators. By automating the deposition process, ROSIE eliminates many of the manual steps that traditionally limit throughput and reproducibility in molecular beam epitaxy. Its compatibility with 300‑mm wafers aligns it with the industry’s move toward larger substrates, enabling scalable production of photonic devices that can be seamlessly integrated into silicon‑based quantum processors.

The new U.S. order is slated for delivery in 2026, with ROSIE’s commercial industrialisation scheduled for 2027. This timeline reflects RIBER’s strategic roadmap to bring the platform from laboratory validation to mass production, thereby accelerating the deployment of silicon photonics solutions that underpin next‑generation quantum technologies. The partnership with the U.S. quantum‑computing leader not only validates ROSIE’s technical capabilities but also positions RIBER at the forefront of the semiconductor industry’s shift toward integrated, high‑performance photonic components.

ROSIE System Enables 300 mm Barium Titanate Growth For Silicon Photonics

Founded in 1964 and headquartered in Bezons, France, RIBER has long been a pioneer in molecular beam epitaxy (MBE) technology. The company announced on 8 September 2025 that a new U.S. quantum‑computing enterprise has placed an order for its ROSIE platform, a fully automated MBE system engineered to deposit barium titanate thin films onto 300‑mm silicon substrates. The order marks the first commercial transaction of ROSIE in the United States and underscores the platform’s readiness for large‑scale silicon photonics production.

The ROSIE system streamlines the growth of the material by automating the deposition sequence, thereby reducing manual intervention and enhancing repeatability. Its design incorporates advanced flux control and real‑time monitoring, which together maintain film uniformity and minimise defect density across the wafer surface. These attributes are essential for the fabrication of electro‑optic modulators that must operate with high fidelity in integrated quantum‑photonic circuits.

The collaboration with the Novo Nordisk Foundation Quantum Computing Programme in Denmark, announced last June, provided a critical validation of ROSIE’s capabilities in a research setting. Building on that partnership, the U.S. order is scheduled for installation in 2026, with a full commercial rollout slated for 2027. This timeline reflects RIBER’s commitment to transitioning the platform from laboratory demonstration to mass production within the next few years.

By securing this order, RIBER is reinforcing its leadership in the evolving silicon‑based photonics arena, positioning its MBE solutions at the heart of next‑generation quantum technologies. The ability to reliably grow barium titanate thin films on 300‑mm wafers will accelerate the deployment of high‑performance electro‑optic devices, thereby supporting the broader semiconductor ecosystem’s shift toward integrated, scalable quantum processors.

Collaboration With Novo Nordisk Foundation Signals Global Confidence In ROSIE

The collaboration announced in June 2025 between RIBER and the Novo Nordisk Foundation Quantum Computing Programme (NQCP) in Denmark marks a pivotal endorsement of the ROSIE platform beyond the United States. NQCP, a research arm of the Novo Nordisk Foundation, is a prominent Danish initiative that funds cutting‑edge quantum‑computing projects. By partnering with NQCP, RIBER secured a research‑grade validation of ROSIE’s ability to grow barium titanate thin films on 300‑mm silicon wafers, a critical material for electro‑optic modulators in integrated photonic circuits.

This partnership demonstrates that ROSIE’s fully automated molecular‑beam epitaxy system can meet the stringent demands of European quantum‑computing research. The collaboration, formally announced last June, provided a testbed for the platform’s flux control, real‑time monitoring, and wafer‑scale uniformity—features that are essential for producing high‑performance electro‑optic devices. The fact that a leading Danish programme has adopted ROSIE for its experimental programmes signals a strong international confidence in the technology, complementing the recent U.S. order and reinforcing RIBER’s position as a supplier of next‑generation photonic components.